# Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS

> **NCT01903291** · — · COMPLETED · sponsor: **Biogen** · enrollment: 333 (actual)

## Conditions studied

- Relapsing Forms of Multiple Sclerosis

## Interventions

- **DRUG:** dimethyl fumarate

## Key facts

- **NCT ID:** NCT01903291
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 333 (ACTUAL)
- **Last updated:** 2016-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01903291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01903291, "Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01903291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*